Your session is about to expire
← Back to Search
Long-Term Treatment for Parkinson's Disease
N/A
Waitlist Available
Research Sponsored by Scion NeuroStim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 months
Awards & highlights
Study Summary
This trial is testing if a longer treatment for symptoms of Parkinson's disease is safe and effective. Only people who completed a previous trial are eligible.
Who is the study for?
This trial is for people who have Parkinson's Disease and were part of the earlier STEM-PD RCT trial. They must be able to consent to participate and commit to attending all study visits.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of a treatment given twice daily for Parkinson's symptoms, but only those who completed the prior STEM-PD RCT can join this extension study.See study design
What are the potential side effects?
Specific side effects are not listed here, but generally, treatments in Parkinson's may include nausea, dizziness, sleepiness, and movement issues. The exact side effects will depend on the particular intervention being tested.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 8 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Movement Disorders
Secondary outcome measures
Change from baseline in The International Parkinson and Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II
Change from baseline in the Clinical Global Impression - Improvement (CGI-I)
Change from baseline in the MDS-UPDRS Part III
+1 moreOther outcome measures
Change from baseline in EncephaLogTM 10m Timed Up and Go (10m TUG)
Change from baseline in EncephaLogTM 3 meter Timed Up and Go Test
Change from baseline in EncephaLogTM finger tapping test
+17 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Experimental Treatment 1Experimental Treatment1 Intervention
Study participants will self-administer ~19-minute treatments twice daily in the home setting using a non-invasive brainstem modulation device. The device has been deemed as a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
Find a Location
Who is running the clinical trial?
Scion NeuroStimLead Sponsor
13 Previous Clinical Trials
465 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not pregnant nor planning to become pregnant during the study.
Research Study Groups:
This trial has the following groups:- Group 1: Experimental Treatment 1
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger